Pfizer Celebrex Safety Representations Draw Cmte. Skepticism
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee members cite concerns with celecoxib studies that used active comparators instead of long-term placebo controls. Pfizer's presentation highlights the company's belief that Celebrex offers an improved gastrointestinal profile, but similar cardiovascular profile, compared to other NSAIDs.